BEDFORD, Mass., Jan. 4 /PRNewswire-FirstCall/ -- Insulet Corporation (Nasdaq: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System, today announced the company will participate in the 28th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present an overview of the Company at 2:00 p.m. PST on Wednesday, January 13, 2010 at The Westin St. Francis in San Francisco, CA.
During the conference presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of the presentation during the event, please visit: http://investors.insulet.com. A replay of the webcast will be available for 30 days.
About Insulet Corporation
Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.
SOURCE Insulet Corporation
Advertisement
During the conference presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of the presentation during the event, please visit: http://investors.insulet.com. A replay of the webcast will be available for 30 days.
Advertisement
About Insulet Corporation
Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.
SOURCE Insulet Corporation
